Table 40Summary of included studies. Comparison 39. Augmenting with trazodone versus continuing with antidepressant

StudyPopulationInterventionComparisonDetails of inadequate response/treatment resistanceComments

Fang 2011

RCT

China

N=92

Mean age (years): NR

Gender (% female): NR

Ethnicity (% BME): NR

Baseline severity: NR (more severe)

Trazodone 100mg/day + paroxetine 20mg/Paroxetine 20mg/dayTRD: Inadequate response to 2 or more adequate treatments from different classes of antidepressants in the current depressive episode (adequate dosages of antidepressants with at least 3-month duration) determined through medical records and/or prospective treatment. 1 week paroxetine lead-in

Treatment length (weeks): 8

Outcomes:

  • Remission
  • Response
  • Quality of life physical component score
  • Quality of life mental component score

BME: black and minority ethnic; NR: not reported; RCT: randomised controlled trial; TRD: treatment-resistant depression

From: Further-line treatment

Cover of Further-line treatment
Further-line treatment: Depression in adults: Evidence review D.
NICE Guideline, No. 222.
Copyright © NICE 2022.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.